# Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

> **NCT06372626** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 93 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **BIOLOGICAL:** ZG005
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06372626
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-07
- **Final completion:** 2026-08
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372626, "Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06372626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*